Institute for Clinical Systems Improvement (ICSI) has adopted a policy of transparency, disclosing potential conflict and competing interests of all individuals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee, Respiratory Steering Committee and the Patient Safety & Reliability Steering Committee).
Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.
Richard Sveum has received less than $10,000 in speaker's fees from Novartis, Merck and Schering.
David Lowe has received $10,000-$50,000 as a member of Speaker's Bureau for Glaxo and Schering.
No other work group members have potential conflicts of interest to disclose.
ICSI's conflict of interest policy and procedures are available for review on ICSI's Web site at www.icsi.org.